Candel Therapeutics, Inc. Insider Selling: Paul Peter Tak Trims Stake

A Form 4 filed with the SEC shows Paul Peter Tak, CEO at Candel Therapeutics, Inc. (CADL), sold 280,245 shares of company stock on 2026-09-10.

The transaction was executed at a price of $11.28 per share, for a total value of approximately $3.16 million.

Under SEC rules, corporate insiders — officers, directors, and holders of more than 10% of a company's shares — are required to report changes in their ownership within two business days of the transaction via Form 4.

Sales by insiders often reflect routine portfolio management or pre-scheduled trading plans rather than a view on the company's prospects.